It’s our business to counter AMR
It’s our business to counter AMR
It’s our business to counter AMR
It’s our business to counter AMR
It’s our business to counter AMR
It’s our business to counter AMR
Antimicrobial resistance (AMR) is a leading global public health challenge that must be tackled. Unchecked, it is projected to be responsible for or contribute to nearly 10 million deaths per year by 2050.
disAMR is working on many fronts to align the science, capital, and policy needed to reshape market dynamics and create incentives that will spur the development of a range of solutions to address the AMR crisis.
Our Vision & Mission
Uniting the Global AMR Collective
disAMR is assembling the organizations and initiatives needed to drive the global response to AMR, making it easier for the AMR community worldwide to identify and connect with the resources they need.
Funding
Directory mapping private investors, public agencies, philanthropic organizations, and public-private partnerships, directing capital toward the AMR response.
Products, Services & Technology
Assembly of the tools advancing the AMR response, including diagnostics, digital tools, contract manufacturing organizations, consultancies, and much more.
Policy, Advocacy & Governmental Organizations
Directory mapping the governmental agencies, policy organizations, and advocacy groups whose decisions determine how quickly and equitably the world responds to AMR.
Collaborations & Consortiums
Directory mapping the partnerships and projects of collaborations and consortia that bridge academia, industry, government, and civil society.
Understanding AMR – Past, Present, and Future
From the earliest moments of the antimicrobial revolution, microbes evolved resistance to the drugs meant to stop them. At first new drugs were developed fast enough to thwart even resistant organisms. But the spread of antimicrobial resistance today has outpaced the development of new therapies. This gap in antibiotic discovery is not due to a failure of scientific imagination. It is instead due to a combination of factors spanning biology, chemistry, clinical development, stewardship, and economics. disAMR explores these factors to reveal both roadblocks and opportunities.
The AMR Therapeutic Landscape
Exploring visualizations of antibiotic approvals by decade, reasons discovery has stalled, antimicrobial therapeutic development compared to other categories of disease, and more.
Explore NowThe AMR Therapeutic Landscape
Exploring visualizations of antibiotic approvals by decade, reasons discovery has stalled, antimicrobial therapeutic development compared to other categories of disease, and more.
Explore Now
The Broken AMR Market
The commercial systems responsible for developing new antimicrobials have steadily deteriorated. Understanding why can help the AMR community create new solutions.
Learn More
Antibiotic Clinical Trial Landscape
Analyzing the antibiotics making their way through the current development pipeline, including a look at progress and structural gaps.
View Analysis
Help Spread the Word
If you are an organization, professional, or individual passionate about countering the threat of AMR, we invite you to help us spread the word. Within disAMR’s Media Resources repository, you’ll find materials for social media posting, logos, images, information about disAMR, and more.
Stay Updated
Stay connected so that you don’t miss the latest AMR insights and updates.
